• 1
    Isomäki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996; 39: 38695.
  • 2
    Adorini L. Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases. Cell Mol Life Sci 1999; 55: 161025.
  • 3
    Moore KW, O'Garra A, De Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11: 16590.
  • 4
    Wilcoxen SC, Kirkman E, Dowdell KC, Stohlman SA. Gender-dependent IL-12 secretion by APC is regulated by IL-10. J Immunol 2000; 164: 623743.
  • 5
    Castro AG, Silva RA, Appelberg R. Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J Immunol 1995; 155: 20139.
  • 6
    Heike M, Schlaak J, Heyl S, Schulze-Bergkamen H, Schmitt U, Meyer zum Buschenfelde KH. Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells. Scand J Immunol 1997; 45: 2216.
  • 7
    Berger S, Balló H, Stutte HJ. Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes. a network of pro- and antiinflammatory cytokines dependent on the antigen-antibody ratio. Eur J Immunol 1996; 26: 1297301.
  • 8
    Berger S, Ballo H, Stutte HJ. Distinct antigen-induced cytokine pattern upon stimulation with antibody-complexed antigen consistent with a Th1 − >Th2-shift. Res Virol 1996; 147: 1038.
  • 9
    Rönnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003; 62: 3742.
  • 10
    Berger S, Chandra R, Balló H, Hildenbrand R, Stutte HJ. Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. Eur J Immunol 1997; 27: 29943000.
  • 11
    Lundwall A, Malmheden I, Stålenheim G, Sjöquist J. Isolation of component C4 of human complement and its polypeptide chains. Eur J Biochem 1981; 117: 1416.
  • 12
    Nilsson UR, Nilsson B. Simplified assays of hemolytic activity of the classical and alternative pathways. J Immunol Meth 1984; 72: 4959.
  • 13
    Van Den Herik-Oudijk IE, Westerdaal NA, Henriquez NV, Capel PJ, Van De Winkel JG. Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. J Immunol 1994; 152: 57485.
  • 14
    Mesri M, Plescia J, Altieri DC. Dual regulation of ligand binding by CD11b I domain. Inhibition of intercellular adhesion and monocyte procoagulant activity by a factor X-derived peptide. J Biol Chem 1998; 273: 7448.
  • 15
    Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Binding kinetics, structure–activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol 2000; 165: 24919.
  • 16
    Wittmann M, Zwirner J, Larsson VA et al. C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol 1999; 162: 67639.
  • 17
    Braun MC, Lahey E, Kelsall BL. Selective suppression of IL-12 production by chemoattractants. J Immunol 2000; 164: 300917.
  • 18
    Ling P, Gately MK, Gubler U et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995; 154: 11627.
  • 19
    Llorente L, Richaud-Patin Y, Wijdenes J et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 4217.
  • 20
    Lacki JK, Samborski W, Mackiewicz SH. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 1997; 16: 2758.
  • 21
    Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998; 10: 1407.
  • 22
    Liu TF, Jones BM. Impaired production of IL-12 in system lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine 1998; 10: 14853.
  • 23
    Bucht A, Larsson P, Weisbrot L et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol 1996; 103: 35767.
  • 24
    Kim W, Min S, Cho M et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol 2000; 119: 17581.
  • 25
    Rönnelid J, Berg L, Rogberg S, Nilsson A, Albertsson K, Klareskog L. Production of T-cell cytokines at the single-cell level in patients with inflammatory arthritides: enhanced activity in synovial fluid compared to blood. Br J Rheumatol 1998; 37: 714.
  • 26
    Peeva E, Fishman AD, Goddard G, Wadler S, Barland P. Rheumatoid arthritis exacerbation caused by exogenous interleukin-12. Arthritis Rheum 2000; 43: 4613.
  • 27
    Kim KN, Watanabe S, Ma Y, Thornton S, Giannini EH, Hirsch R. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. J Immunol 2000; 164: 157681.
  • 28
    Chomarat P, Vannier E, Dechanet J et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995; 154: 14329.
  • 29
    Golab J, Zagozdzon R. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies. Int J Mol Med 1999; 3: 53744.
  • 30
    Salazar-Onfray F. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol 1999; 16: 8694.
  • 31
    Segal-Eiras A, Croce MV. Immune complexes in human malignant tumours. A review. Allergol Immunopathol 1984; 12: 22532.
  • 32
    Gorczynski RM, Kilburn DG, Knight RA, Norbury C, Parker DC, Smith JB. Nonspecific and specific immunosuppression in tumour-bearing mice by soluble immune complexes. Nature 1975; 254: 1413.
  • 33
    Jerry LM, Lewis MG, Cano P. Anergy, anti-antibodies and immune complex disease: a syndrome of disordered immune regulation in human cancer. In: MartinM, DionneL, eds. Immunocancerology in solid tumors. New York: Stratton, 1976: 6379.
  • 34
    Kilburn DG, Fairhurst M, Levy JG, Whitney RB. Synergism between immune complexes and serum from tumor-bearing mice in the suppression of mitogen responses. J Immunol 1976; 117: 16127.